Is FATE or OCS more profitable?

Fate Therapeutics has a net margin of -2,056.79% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Fate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fate Therapeutics -2,056.79% -58.89% -39.39% Oculis -8,460.67% -56.78% -45.62%

Does the media refer more to FATE or OCS?

In the previous week, Oculis had 10 more articles in the media than Fate Therapeutics. MarketBeat recorded 14 mentions for Oculis and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.00 beat Oculis' score of -0.16 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, FATE or HROW?

Harrow has higher revenue and earnings than Fate Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 33.48 -$136.32M -$1.09 N/A Harrow $272.30M 4.53 -$5.14M -$0.41 N/A

Is FATE or HROW more profitable?

Harrow has a net margin of -5.57% compared to Fate Therapeutics' net margin of -2,056.79%. Harrow's return on equity of 19.59% beat Fate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Fate Therapeutics -2,056.79% -58.89% -39.39% Harrow -5.57% 19.59% 2.26%

Does the media refer more to FATE or HROW?

In the previous week, Fate Therapeutics had 1 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Harrow. Harrow's average media sentiment score of 0.06 beat Fate Therapeutics' score of 0.00 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, COAG or FATE?

Hemab Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Fate Therapeutics $6.65M 33.48 -$136.32M -$1.09 N/A

Does the media favor COAG or FATE?

In the previous week, Fate Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.00 equaled Fate Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FATE or WVE?

In the previous week, Fate Therapeutics had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for WAVE Life Sciences. Fate Therapeutics' average media sentiment score of 0.00 equaled WAVE Life Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fate Therapeutics (FATE) Competitors

$1.91 -0.07 (-3.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.99 +0.08 (+4.19%)

As of 07:52 PM Eastern

Compare

FATE vs. OCS, HROW, COAG, WVE, and MPLT

Should you buy Fate Therapeutics stock or one of its competitors? MarketBeat compares Fate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fate Therapeutics include Oculis (OCS), Harrow (HROW), Hemab Therapeutics (COAG), WAVE Life Sciences (WVE), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Fate Therapeutics compare to Oculis?

Fate Therapeutics (NASDAQ:FATE) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Fate Therapeutics has a net margin of -2,056.79% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Oculis	-8,460.67%	-56.78%	-45.62%

In the previous week, Oculis had 10 more articles in the media than Fate Therapeutics. MarketBeat recorded 14 mentions for Oculis and 4 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 0.00 beat Oculis' score of -0.16 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oculis has lower revenue, but higher earnings than Fate Therapeutics. Oculis is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	33.48	-$136.32M	-$1.09	N/A
Oculis	$1.45M	428.25	-$119.44M	-$2.13	N/A

Fate Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 168.32%. Oculis has a consensus price target of $38.33, indicating a potential upside of 257.92%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fate Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Oculis has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Summary

Fate Therapeutics beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Harrow?

Fate Therapeutics (NASDAQ:FATE) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Fate Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 168.32%. Harrow has a consensus price target of $69.43, indicating a potential upside of 109.75%. Given Fate Therapeutics' higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Harrow has a net margin of -5.57% compared to Fate Therapeutics' net margin of -2,056.79%. Harrow's return on equity of 19.59% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Harrow	-5.57%	19.59%	2.26%

In the previous week, Fate Therapeutics had 1 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Harrow. Harrow's average media sentiment score of 0.06 beat Fate Therapeutics' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Harrow has higher revenue and earnings than Fate Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	33.48	-$136.32M	-$1.09	N/A
Harrow	$272.30M	4.53	-$5.14M	-$0.41	N/A

Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Harrow beats Fate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Fate Therapeutics (NASDAQ:FATE) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Hemab Therapeutics presently has a consensus price target of $41.75, suggesting a potential upside of 63.41%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 168.32%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

97.5% of Fate Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hemab Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Hemab Therapeutics' return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

In the previous week, Fate Therapeutics had 2 more articles in the media than Hemab Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.00 equaled Fate Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics has higher earnings, but lower revenue than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Fate Therapeutics	$6.65M	33.48	-$136.32M	-$1.09	N/A

Summary

Hemab Therapeutics and Fate Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Fate Therapeutics compare to WAVE Life Sciences?

Fate Therapeutics (NASDAQ:FATE) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Fate Therapeutics had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for Fate Therapeutics and 1 mentions for WAVE Life Sciences. Fate Therapeutics' average media sentiment score of 0.00 equaled WAVE Life Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fate Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	33.48	-$136.32M	-$1.09	N/A
WAVE Life Sciences	$42.73M	25.67	-$204.38M	-$1.06	N/A

WAVE Life Sciences has a net margin of -255.70% compared to Fate Therapeutics' net margin of -2,056.79%. WAVE Life Sciences' return on equity of -56.76% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market.

Fate Therapeutics currently has a consensus target price of $5.13, indicating a potential upside of 168.32%. WAVE Life Sciences has a consensus target price of $27.25, indicating a potential upside of 378.07%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

WAVE Life Sciences beats Fate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Fate Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Fate Therapeutics (NASDAQ:FATE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Maplight Therapeutics presently has a consensus target price of $37.78, suggesting a potential upside of 28.23%. Fate Therapeutics has a consensus target price of $5.13, suggesting a potential upside of 168.32%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.00
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Maplight Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Maplight Therapeutics' return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Fate Therapeutics has higher revenue and earnings than Maplight Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Fate Therapeutics	$6.65M	33.48	-$136.32M	-$1.09	N/A

97.5% of Fate Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Fate Therapeutics had 4 more articles in the media than Maplight Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 0 mentions for Maplight Therapeutics. Fate Therapeutics' average media sentiment score of 0.00 beat Maplight Therapeutics' score of -0.63 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Maplight Therapeutics	Negative
Fate Therapeutics	Neutral

Summary

Fate Therapeutics beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FATE vs. The Competition

Export

Metric	Fate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$230.79M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-1.75	18.61	23.92	23.74
Price / Sales	33.48	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.06	8.04	10.28	6.78
Net Income	-$136.32M	$23.89M	$3.57B	$337.51M
7 Day Performance	-30.29%	-5.97%	-1.43%	-2.72%
1 Month Performance	-20.08%	2.78%	3.27%	1.87%
1 Year Performance	19.38%	36.26%	23.37%	26.60%

Fate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FATE Fate Therapeutics	2.8739 of 5 stars	$1.91 -3.5%	$5.13 +168.3%	+23.8%	$230.79M	$6.65M	N/A	550	Analyst Forecast
OCS Oculis	3.1199 of 5 stars	$14.51 -36.1%	$40.44 +178.7%	-43.7%	$1.32B	$1.45M	N/A	2	News Coverage High Trading Volume
HROW Harrow	4.4217 of 5 stars	$34.11 -3.1%	$69.43 +103.5%	+12.2%	$1.31B	$272.30M	N/A	180	Positive News
COAG Hemab Therapeutics	4.3416 of 5 stars	$27.13 -4.8%	$41.75 +53.9%	N/A	$1.27B	N/A	N/A	72	Quiet Period Expiration Gap Up
WVE WAVE Life Sciences	2.3642 of 5 stars	$6.26 -4.9%	$27.25 +335.3%	-20.6%	$1.27B	$71.80M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Competitors

FATE vs. OCS, HROW, COAG, WVE, and MPLT

How does Fate Therapeutics compare to Oculis?

Summary

How does Fate Therapeutics compare to Harrow?

Summary

How does Fate Therapeutics compare to Hemab Therapeutics?

Summary

How does Fate Therapeutics compare to WAVE Life Sciences?

Summary

How does Fate Therapeutics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fate Therapeutics (FATE) Competitors

FATE vs. OCS, HROW, COAG, WVE, and MPLT

How does Fate Therapeutics compare to Oculis?

Is FATE or OCS more profitable?

Does the media refer more to FATE or OCS?

Which has better valuation & earnings, FATE or OCS?

Do analysts rate FATE or OCS?

Do institutionals and insiders believe in FATE or OCS?

Which has more risk & volatility, FATE or OCS?

Summary

How does Fate Therapeutics compare to Harrow?

Do analysts rate FATE or HROW?

Is FATE or HROW more profitable?

Does the media refer more to FATE or HROW?

Do institutionals and insiders have more ownership in FATE or HROW?

Which has preferable valuation and earnings, FATE or HROW?

Which has more volatility and risk, FATE or HROW?

Summary

How does Fate Therapeutics compare to Hemab Therapeutics?

Do analysts prefer COAG or FATE?

Do insiders & institutionals believe in COAG or FATE?

Is COAG or FATE more profitable?

Does the media favor COAG or FATE?

Which has preferable valuation and earnings, COAG or FATE?

Summary

How does Fate Therapeutics compare to WAVE Life Sciences?

Does the media refer more to FATE or WVE?

Which has stronger earnings and valuation, FATE or WVE?

Is FATE or WVE more profitable?

Do insiders and institutionals believe in FATE or WVE?

Which has more risk & volatility, FATE or WVE?

Do analysts recommend FATE or WVE?

Summary

How does Fate Therapeutics compare to Maplight Therapeutics?

Do analysts recommend MPLT or FATE?

Is MPLT or FATE more profitable?

Which has higher valuation and earnings, MPLT or FATE?

Do institutionals and insiders hold more shares of MPLT or FATE?

Does the media refer more to MPLT or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools